Anemia of Chronic Kidney Disease Clinical Trial
Official title:
Phase III, Multicentre, Double-blind, Randomised, Parallel, Equivalence Clinical Trial to Assess Efficacy, Safety of Megalabs® Recombinant i/v Human Erythropoietin Compared to Eprex® in Anaemia in Patients With Chronic Kidney Disease
Phase III, multicentre, double-blind, randomised, parallel, equivalence clinical trial to determine the efficacy, safety and immunogenicity of Megalabs® recombinant human alfa epoetin for subcutaneous use, compared to Eprex® (Janssen-Cilag Farmacêutica Ltda.), in the treatment of anaemia in participants with chronic renal disease, dependent on haemodialysis
Patients with chronic kidney disease undergoing hemodialysis will be administered human recombinant alfa epoetin to revert anemia. Hemoglobin, hematocrit and reticulocyte counts will be assessed. Immunogenicity will be evaluated through bi-weekly Anti Drug Antibody determination. Test drug and comparator drug will be compared to evaluate biosimilarity. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03325621 -
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02198495 -
Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients
|
Phase 4 | |
Suspended |
NCT03193073 -
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
|
N/A | |
Completed |
NCT02581124 -
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
|
Phase 1 | |
Completed |
NCT02268994 -
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
|
Phase 3 | |
Completed |
NCT04543812 -
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
|
Phase 3 | |
Recruiting |
NCT05900635 -
Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients
|
Phase 4 | |
Completed |
NCT04667533 -
Desidustat in the Treatment of Chemotherapy Induced Anemia
|
Phase 1 | |
Completed |
NCT03731741 -
Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?
|
Phase 2 | |
Completed |
NCT02787824 -
Periodic Versus Continuous IV Iron Supplementation in HD Patients
|
Phase 4 | |
Completed |
NCT03431623 -
CKD-11101 Phase 3 SC Study
|
Phase 3 | |
Completed |
NCT01971164 -
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
|
Phase 1 | |
Recruiting |
NCT01532349 -
Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT05698420 -
Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
|
||
Completed |
NCT03427801 -
Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
|
||
Recruiting |
NCT03521713 -
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
|
Phase 3 | |
Active, not recruiting |
NCT02754167 -
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02805244 -
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
|
Phase 1 | |
Completed |
NCT03428594 -
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
|
Phase 3 | |
Recruiting |
NCT06463236 -
Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients
|
N/A |